GlassScriptPhysician profile
James M Mcneely
NPI 1598829863
$2,624.04
in general payments reported to CMS, 2019-2025
35 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $476 · 2021: $702 · 2022: $458 · 2023: $229 · 2024: $189 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $376.40 | 2019-2025 | |
| Novo Nordisk INC | $370.44 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $323.99 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $303.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $230.09 | 2021-2023 | |
| Abbott Laboratories | $83.26 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $82.50 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $80.68 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $73.08 | 2021-2022 | |
| Esperion Therapeutics, INC. | $66.69 | 2020-2022 | |
| Exact Sciences Corporation | $62.85 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $59.71 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.70 | 2022-2024 | Ofev, Jardiance |
| Astrazeneca Pharmaceuticals LP | $45.77 | 2019-2025 | Airsupra |
| Eisai INC. | $44.01 | 2021-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $36.79 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $28.79 | 2025 | Neffy |
| Kowa Pharmaceuticals America, INC. | $25.42 | 2021 | |
| Dexcom, INC. | $23.64 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $21.88 | 2022 | |
| Daiichi Sankyo INC. | $20.81 | 2021 | |
| Astellas Pharma US INC | $20.27 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.84 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.62 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $18.46 | 2023 | Arexvy, Shingrix |
| Grifols USA, LLC | $15.54 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.74 | 2025 | Voquezna |
| Sanofi Pasteur INC. | $13.91 | 2019 | |
| Hikma Pharmaceuticals USA | $13.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.92 | 2020 | |
| Circassia INC. | $12.45 | 2019 | |
| Collegium Pharmaceutical, INC. | $12.44 | 2021 | |
| Gilead Sciences, INC. | $12.16 | 2020 | |
| Allergan, INC. | $11.94 | 2020 | |
| Genentech USA, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcneely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.